RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. https://t.co/Nbo0LKgb6Q
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
@StephenJ_Hughes
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
RT @emilylheil: We ❤️ new antibiotics for treating MDR gram-negatives. Our awesome ID resident @MandeeNoval and the rest of the @UMMC ID ph…
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
RT @emilylheil: We ❤️ new antibiotics for treating MDR gram-negatives. Our awesome ID resident @MandeeNoval and the rest of the @UMMC ID ph…
RT @emilylheil: We ❤️ new antibiotics for treating MDR gram-negatives. Our awesome ID resident @MandeeNoval and the rest of the @UMMC ID ph…
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
Always amazed with the clinically relevant articles that @emilylheil publishes
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
RT @emilylheil: We ❤️ new antibiotics for treating MDR gram-negatives. Our awesome ID resident @MandeeNoval and the rest of the @UMMC ID ph…
RT @davidvanduin: Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and…
Very nice review by @emilylheil and colleagues on ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam, and cefiderocol. https://t.co/CvbgMciTbe
RT @emilylheil: We ❤️ new antibiotics for treating MDR gram-negatives. Our awesome ID resident @MandeeNoval and the rest of the @UMMC ID ph…
RT @emilylheil: We ❤️ new antibiotics for treating MDR gram-negatives. Our awesome ID resident @MandeeNoval and the rest of the @UMMC ID ph…
RT @emilylheil: We ❤️ new antibiotics for treating MDR gram-negatives. Our awesome ID resident @MandeeNoval and the rest of the @UMMC ID ph…
RT @emilylheil: We ❤️ new antibiotics for treating MDR gram-negatives. Our awesome ID resident @MandeeNoval and the rest of the @UMMC ID ph…
We ❤️ new antibiotics for treating MDR gram-negatives. Our awesome ID resident @MandeeNoval and the rest of the @UMMC ID pharmacy team (@ClaeysKcclaeys, @MaryBanoub) summarized the latest on the newest beta-lactam options here: https://t.co/hSLjW1BsBc
The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. https://t.co/rNh44jOsyW